Literature DB >> 6700669

Importance of raised growth hormone levels in mediating the metabolic derangements of diabetes.

M Press, W V Tamborlane, R S Sherwin.   

Abstract

To evaluate the importance of the raised levels of growth hormone that characterize poor diabetic control, we gave growth hormone for 21 to 45 hours in the form of hourly 100-micrograms pulses to 14 diabetics being treated by insulin pump. Insulin-pump settings and meals were kept constant. Mean 24-hour levels of growth hormone (+/- S.E.M.) rose from 8 +/- 1 to 16 +/- 2 ng per milliliter--values identical to those observed in 12 other patients with poorly controlled diabetes (17 +/- 3 ng per milliliter). Plasma glucose concentrations doubled within 8 to 10 hours and remained elevated until growth hormone was discontinued (fasting glucose level rose from 86 +/- 11 to 204 +/- 17 mg per deciliter at 18 hours and to 240 +/- 20 mg per deciliter at 42 hours). The hyperglycemia was due mainly to a marked stimulation of hepatic glucose production that occurred without changes in levels of free insulin or glucagon. Levels of circulating free fatty acids, ketones, and branched-chain amino acids were also increased. The moderate elevations in growth hormone levels that occur in poorly controlled diabetes can themselves reproduce the whole spectrum of abnormal metabolic fuel concentrations that are associated with poor diabetic control, despite optimized insulin treatment. Thus, hypersecretion of growth hormone may be the cause as much as the consequence of poor diabetic control.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6700669     DOI: 10.1056/NEJM198403293101302

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  22 in total

1.  Adipocyte JAK2 mediates growth hormone-induced hepatic insulin resistance.

Authors:  Kevin C Corbit; João Paulo G Camporez; Jennifer L Tran; Camella G Wilson; Dylan A Lowe; Sarah M Nordstrom; Kirthana Ganeshan; Rachel J Perry; Gerald I Shulman; Michael J Jurczak; Ethan J Weiss
Journal:  JCI Insight       Date:  2017-02-09

2.  Stabilisation of diabetic retinopathy following simultaneous pancreas and kidney transplant.

Authors:  I A Pearce; B Ilango; R A Sells; D Wong
Journal:  Br J Ophthalmol       Date:  2000-07       Impact factor: 4.638

3.  Dawn phenomenon in type 1 (insulin-dependent) diabetic adolescents: influence of nocturnal growth hormone secretion.

Authors:  B Beaufrère; M Beylot; C Metz; A Ruitton; R François; J P Riou; R Mornex
Journal:  Diabetologia       Date:  1988-08       Impact factor: 10.122

Review 4.  Diabetic retinopathy.

Authors:  E M Kohner
Journal:  BMJ       Date:  1993-11-06

5.  Combined hormonal infusion simulates the metabolic response to injury.

Authors:  P Q Bessey; J M Watters; T T Aoki; D W Wilmore
Journal:  Ann Surg       Date:  1984-09       Impact factor: 12.969

Review 6.  Nutrition, hormones, and breast cancer: is insulin the missing link?

Authors:  R Kaaks
Journal:  Cancer Causes Control       Date:  1996-11       Impact factor: 2.506

7.  The effects of different plasma insulin concentrations on lipolytic and ketogenic responses to epinephrine in normal and type 1 (insulin-dependent) diabetic humans.

Authors:  A Avogaro; A Valerio; L Gnudi; A Maran; M Miola; E Duner; C Marescotti; E Iori; A Tiengo; R Nosadini
Journal:  Diabetologia       Date:  1992-02       Impact factor: 10.122

8.  Acute mental stress impairs insulin sensitivity in IDDM patients.

Authors:  E Moberg; M Kollind; P E Lins; U Adamson
Journal:  Diabetologia       Date:  1994-03       Impact factor: 10.122

9.  Increased renal Akt/mTOR and MAPK signaling in type I diabetes in the absence of IGF type 1 receptor activation.

Authors:  Daniel Landau; Renanah Eshet; Ariel Troib; Yotam Gurman; Yu Chen; Ralph Rabkin; Yael Segev
Journal:  Endocrine       Date:  2009-04-23       Impact factor: 3.633

10.  Glucose tolerance and insulin release in adolescent female.

Authors:  L Benassi; G Tridenti; N Orlandi; A Pezzarossa
Journal:  J Endocrinol Invest       Date:  1991-10       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.